Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7370074 | 0.84 | HTT (0.57) | HTTSMN1; SMN2KDM4EIDO1CA12 | |
| SCHEMBL48525 | 0.82 | HTT (0.66) | HTTSMN1; SMN2KDM4ECTBP2PKM | |
| SCHEMBL3805022 | 0.80 | HTT (0.53) | HTTSMN1; SMN2KDM4EIDO1CA12 | |
| SCHEMBL22481094 | 0.80 | HTT (0.53) | HTTSMN1; SMN2KDM4EIDO1CA12 | |
| SCHEMBL3628705 | 0.79 | HTT (0.68) | HTTSMN1; SMN2KDM4ECTBP2PKM | |
| SCHEMBL23795055 | 0.79 | SMN1; SMN2 (0.58) | HTTSMN1; SMN2KDM4EIDO1PKM | |
| SCHEMBL14451475 | 0.79 | SMN1; SMN2 (0.53) | HTTSMN1; SMN2KDM4EIDO1CA12 | |
| SCHEMBL3662312 | 0.79 | KDM4E (0.62) | HTTSMN1; SMN2KDM4EIDO1CTBP2 | |
| SCHEMBL6650453 | 0.77 | NQO1 (0.61) | SMN1; SMN2KDM4ELTA4HALDH1A1MEN1 | |
| SCHEMBL10969285 | 0.77 | ALDH1A1 (0.55) | HTTSMN1; SMN2KDM4EIDO1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558954-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF R-6-HYDROXY-8-[1-HYDROXY-2-[2-(4-METHOXYPHENYL)-1,1-DIMETHYLETHYLAMINOETHYL]-2H-1,4-BENZOXAZIN-3(4H)-ONE HYDROCHLORIDE | INKE, S.A. (ES) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018114887-A1 | IMPROVED PROCESS FOR THE MANUFACTURE OF R-6-HYDROXY-8-[1-HYDROXY-2-[2-(4-METHOXYPHENYL)-1,1-DIMETHYLETHYLAMINOETHYL]-2H-1,4-BENZOXAZIN-3(4H)-ONE HYDROCHLORIDE | LABORATORIOS LESVI, S.L. (ES) | 2018-06-28 | — | — | WO | disclosed |
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| EP-1931994-A2 | MOLECULAR MARKERS ASSOCIATED WITH BONE METASTASIS | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | MISSBACH MARTIN | 2007-06-14 | — | — | US | disclosed |
| WO-2007038397-A2 | MOLECULAR MARKERS ASSOCIATED WITH BONE METASTASIS | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| WO-1994019335-A1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-09-01 | — | — | WO | disclosed |
| US-5272268-A | Dipeptide derivatives | SHIONOGI & CO., LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
| US-5223615-A | Hypotensive agents | SHIONOGI & CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5194608-A | Hypotensive agents; inhibits renin-angiotensin system | SHIONOGI & CO., LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0389162-A1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0365678-A1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1990-05-02 | — | — | EP | disclosed |
| US-4396629-A | HYPOTENSIVE AGENTS; ADRENERIGIC BLOCKING AGENTS | STERLING DRUG INC. (US) | 1983-08-02 | — | — | US | disclosed |
| US-4104402-A | BRONCHODILATORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-08-01 | — | — | US | disclosed |
| US-4035512-A | Aminotetralols | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-07-12 | — | — | US | disclosed |
| US-4010202-A | TREATMENT OF ASTHMA AND ARRHYTHMIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | CTSK, CTSB, CTSZ | HTT 3071/4885SMN1; SMN2 4067/4885KDM4E 1710/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | HTT 3597/4885SMN1; SMN2 4701/4885KDM4E 2761/4885 |
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | BST2, BSG, CD44 | HTT 4875/4885SMN1; SMN2 4870/4885KDM4E 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.